Search Results for "Today"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Today. Results 11 to 20 of 21 total matches.

Corneal Surgery for Correction of Refractive Errors

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 1999  (Issue 1068)
Waring et al, Arch Ophthalmol, 112:1298, 1994). RK is rarely performed today. INTRACORNEAL RINGS ...
All refractive corneal surgery reshapes the cornea to redirect light rays so that they focus on the retine....
Med Lett Drugs Ther. 1999 Dec 17;41(1068):122-3 |  Show IntroductionHide Introduction

Remimazolam (Byfavo) for Short-Term Procedural Sedation

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
. Drugs Today (Barc) 2021; 57:337. 2. DK Rex et al. A phase III study evaluating the efficacy and safety ...
The FDA has approved remimazolam (Byfavo – Acacia Pharma), an ultra-short-acting IV benzodiazepine, for induction and maintenance of sedation in adults undergoing procedures of up to 30 minutes' duration.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):26-8 |  Show IntroductionHide Introduction

Prostate Cancer Screening

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
diagnosed with prostate cancer in the US today (even with low-grade, early-stage disease) choose ...
The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen (PSA) to screen men < 75 years old for prostate cancer and has recommended against screening men > 75 years old.
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85-6 |  Show IntroductionHide Introduction

Clarithromycin in Patients with Coronary Artery Disease

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
prolongation, TdP and sudden death. Cardiology Today 2017 Sept (epub). 6. DN Juurlink. The cardiovascular ...
The FDA has warned that use of the macrolide antibiotic clarithromycin (Biaxin, and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
Med Lett Drugs Ther. 2018 May 21;60(1547):89-90 |  Show IntroductionHide Introduction

Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023  (Issue 1692)
Today 2019; 24:606. 5. KM Deligiannidis et al. Zuranolone for the treatment of postpartum depression ...
The FDA has approved the oral GABAA receptor modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression (PPD). Zuranolone is the second drug to be approved for this indication; brexanolone (Zulresso), another GABAA receptor modulator, was approved for IV treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3   doi:10.58347/tml.2023.1692a |  Show IntroductionHide Introduction

Lasik and Its Alternatives: An Update

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 2004  (Issue 1174)
account for only a small percentage of refractive surgery procedures today. PHAKIC INTRAOCULAR LENSES ...
Since the last Medical Letter article on surgical correction of refractive errors (Volume 41, page 122, 1999), some new techniques have been tried and new results have been reported.
Med Lett Drugs Ther. 2004 Jan 19;46(1174):5-7 |  Show IntroductionHide Introduction

Acupuncture

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
that acupuncture was used in China as the only anesthetic in major surgery, 7 acupuncture today is regarded ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Med Lett Drugs Ther. 2006 May 8;48(1234):38-9 |  Show IntroductionHide Introduction

Phexxi - A Nonhormonal Contraceptive Gel

   
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020  (Issue 1605)
: difficult to insert, less widely available Male: allergic reactions, breakage possible Sponge Today ...
The FDA has approved Phexxi (Evofem), a nonhormonal prescription-only vaginal gel containing lactic acid, citric acid, and potassium bitartrate, for prevention of pregnancy. The gel is intended for on-demand contraception; it is not effective when used after intercourse. It was previously approved for use as a vaginal lubricant (Amphora), but was never marketed.
Med Lett Drugs Ther. 2020 Aug 24;62(1605):129-32 |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
High failure rate; allergic reactions; poor acceptability; breakage possible Sponge Today 14%/27%7 ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
disease: a review. JAMA 2020; 323:548. 3. SH Fox and AW Lang. "Don't delay, start today": delaying ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction